Business
PAOG Advances Independent Research of Cannabis Drug RespRx
PAOG Advances Independent Research of Cannabis Drug RespRx.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Advances Independent Research of Cannabis Drug RespRx\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Advances Independent Research of Cannabis Drug RespRx\nPR Newswire\nSANDUSKY, Ohio, Oct. 7, 2020\n\n\n\nSANDUSKY, Ohio, Oct. 7, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) is rapidly moving forward with multiple independent reviews of PAOG's RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  The company anticipates a series of independent research engagement announcements over the coming weeks.\nOn July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).  RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\" \nIn an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. \nWith RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.\nThe expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research.  Two studies in particular, both of which highlight the research behind GW Pharmaceuticals' cannabinoid treatments, shed light on PAOG's wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.\nOne of the two studies is focused on CBD and the other on THC.  The research seems t...